Elina Koustoumpardi

Primary location

8 Finsbury Circus
London, EC2M 7EA, UK

Elina Koustoumpardi

Principal

Elina Koustoumpardi is a Senior Consultant to CRA’s European Competition Practice. She has more than  15 years experience in the application of economic theory and empirical techniques to competition law cases.

She has advised clients in:

  • Complex merger investigations involving both horizontal and vertical effects, including LSE/Refinitiv, Nexi/SIA, Novelis/Aleris, Ethniki/CVC and others, in front of the European Commission and national competition authorities (Greece, Italy, South Africa, UK);
  • Abuse of dominance investigations by competition authorities, involving exploitative as well as exclusionary practices (in sectors such as chipsets, telecoms, packaging materials, excessive pricing in pharmaceuticals); and
  • Litigations, involving estimation of damages acting either on behalf of defendants or complainants in cartels (including GIS, shipping, construction and others) and abuse of dominance investigations.

She has worked on cases in a range of sectors with a focus more recently on payments, pharmaceuticals and healthcare

Education

  • B.A. Politics, Philosophy & Economics, University of Oxford
  • M.Sc Economics, University College London

Cases

Microsoft / Activision

Read More

Ethniki / CVC

Read More

Nexi / SIA

Read More

London Stock Exchange Group/Refinitiv

Read More

Flynn/Pfizer

Read More

Novelis/Aleris

Read More

TEVA/Mylan

Read More

Phenytoin Sodium

Read More

Abbott/Alere

Read More

Telenor (Margin Squeeze)

Read More

Coffee

Read More

News Articles

CMA announces it will clear Microsoft's acquisition of Activision Blizzard

Read More

European Commission closes investigations into retail alliances

Read More

CMA clears Capco’s acquisition of Shaftesbury

Read More

EC unconditionally clears CVC’s acquisition of Ethniki

Read More

ICA clears merger between Nexi and SIA

Read More

London Stock Exchange Group’s acquisition of Refinitiv conditionally approved by the European Commission

Read More

EC clears Novelis’ $2.6 billion acquisition of Aleris, subject to conditions

Read More

Publications

Excessive pricing cases in the pharmaceutical industry

Read More